Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Glioma × Eflornithine × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Adenomatous Polyposis Coli 2 Urinary Bladder Neoplasms 1 Precancerous Conditions 1 Glioma 1 Colorectal Neoplasms 1 Colonic Polyps 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Temozolomide 7 Radiotherapy 7 Lomustine 6 Procarbazine 4 Carmustine 4 Bevacizumab 4 Vincristine 3 Administration, Oral 2 vorasidenib 1 fluorodopa F 18 1 contrast agent BR1 1 carmustine, poliferprosan 20 drug combination 1 Valproic Acid 1 Tranexamic Acid 1 Trabedersen 1 TIC10 compound 1 Surgical Procedures, Operative 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy, Conformal 1 Radiation 1 Microbubbles 1 Methylphenidate 1 Methods 1 Isotretinoin 1 Infusions, Intravenous 1 IL13-PE38 1 Fentanyl 1 Eflornithine 1 Drug Delivery Systems 1 Donepezil 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02796261 2022-01-21

STELLAR

Orbus Therapeutics, Inc.

Phase 3 Unknown

Astrocytoma, Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡